No-Deal Brexit May Lead To A Fragmented Market
Panellists at the UK’s Westminster Health Forum conference on Biosimilars in the NHS united over concerns of a no-deal Brexit and what it would mean for generics and biosimilars producers.
You may also be interested in...
Draft legislation has been published by the UK’s Intellectual Property Office to ensure that the EU’s supplementary certificate protection manufacturing waiver will continue to function in the case of a no-deal Brexit outcome.
The UK’s participation in Europe’s unified patent court (UPC) hangs in the balance in the event of no deal being reached on the UK’s ‘Brexit’ departure from the European Union (EU) in March 2019, according to guidance issued by the UK government on intellectual-property (IP) issues relating to pharmaceuticals, including patents and supplementary protection certificates (SPCs). But even with no deal, the UK will continue to offer SPCs.
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.